0001237899-13-000053.txt : 20130920 0001237899-13-000053.hdr.sgml : 20130920 20130920163346 ACCESSION NUMBER: 0001237899-13-000053 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20130918 FILED AS OF DATE: 20130920 DATE AS OF CHANGE: 20130920 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: REGENERON PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000872589 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 133444607 STATE OF INCORPORATION: NY FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 777 OLD SAW MILL RIVER RD CITY: TARRYTOWN STATE: NY ZIP: 10591-6707 BUSINESS PHONE: 9143477000 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: VAGELOS P ROY CENTRAL INDEX KEY: 0001013064 STANDARD INDUSTRIAL CLASSIFICATION: AIRCRAFT [3721] STATE OF INCORPORATION: MD FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-19034 FILM NUMBER: 131108245 4 1 edgardoc.xml PRIMARY DOCUMENT X0306 4 2013-09-18 0 0000872589 REGENERON PHARMACEUTICALS INC REGN 0001013064 VAGELOS P ROY 777 OLD SAW MILL RIVER ROAD TARRYTOWN NY 10591 1 1 0 0 Chairman of the Board Common Stock 2013-09-18 4 M 0 312500.0 13.0 A 378259 D Common Stock 2013-09-18 4 F 0 13346.0 304.38 D 364913 D Common Stock 2013-09-18 4 F 0 153798.0 304.38 D 211115 D Common Stock 2013-09-19 4 S 0 61159.0 300.34 D 149956 D Common Stock 2013-09-19 4 S 0 21179.0 301.42 D 128777 D Common Stock 2013-09-19 4 S 0 10742.0 302.86 D 118035 D Common Stock 2013-09-19 4 S 0 6780.0 303.49 D 111255 D Common Stock 2013-09-19 4 S 0 11286.0 304.8 D 99969 D Common Stock 2013-09-19 4 S 0 13126.0 305.28 D 86843 D Common Stock 2013-09-19 4 S 0 5084.0 306.46 D 81759 D Common Stock 2013-09-19 4 S 0 4500.0 308.4 D 77259 D Common Stock 2013-09-19 4 S 0 2600.0 309.84 D 74659 D Common Stock 2013-09-19 4 S 0 8900.0 310.18 D 65759 D Common Stock 2013-07-05 5 G 0 921.0 0.0 D 159267 I by CLAT Common Stock 73597 I by GRAT Common Stock 2352 I By 401(k) Plan Common Stock 15162 I by GRAT Common Stock 3 I by GRAT Common Stock 114750 I by Spouse as Trustee Common Stock 1203 I by trust for grandch Non-Qualified Stock Option (right to buy) 13.0 2013-09-18 4 M 0 312500.0 0.0 D 2013-12-15 Common Stock 312500 0 D Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Represents volume-weighted average price of sales of 61,159 shares of Company stock on September 19, 2013 at prices ranging from $300.00 to $300.95. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 19, 2013 at each separate price. Represents volume-weighted average price of sales of 21,179 shares of Company stock on September 19, 2013 at prices ranging from $301.00 to $301.74. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 19, 2013 at each separate price. Represents volume-weighted average price of sales of 10,742 shares of Company stock on September 19, 2013 at prices ranging from $302.56 to $302.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 19, 2013 at each separate price. Represents volume-weighted average price of sales of 6,780 shares of Company stock on September 19, 2013 at prices ranging from $303.07 to $303.83. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 19, 2013 at each separate price. Represents volume-weighted average price of sales of 11,286 shares of Company stock on September 19, 2013 at prices ranging from $304.19 to $304.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 19, 2013 at each separate price. Represents volume-weighted average price of sales of 13,126 shares of Company stock on September 19, 2013 at prices ranging from $305.00 to $300.94. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 19, 2013 at each separate price. Represents volume-weighted average price of sales of 5,084 shares of Company stock on September 19, 2013 at prices ranging from $306.10 to $306.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 19, 2013 at each separate price. Represents volume-weighted average price of sales of 4,500 shares of Company stock on September 19, 2013 at prices ranging from $308.05 to $308.70. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 19, 2013 at each separate price. Represents volume-weighted average price of sales of 2,600 shares of Company stock on September 19, 2013 at prices ranging from $309.09 to $309.94. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 19, 2013 at each separate price. Represents volume-weighted average price of sales of 8,900 shares of Company stock on September 19, 2013 at prices ranging from $310.00 to $310.51. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 19, 2013 at each separate price. By a trust for the benefit of certain grandchildren of the reporting person, of which the reporting person and/or the spouse of the reporting person is trustee. The stock option becomes 100% exercisable one year after the date of grant. By: /s/*Douglas McCorkle as attorney-in-fact For: /s/**P. Roy Vagelos 2013-09-20 EX-24 2 bny13229_bny1prv.txt EDGAR SUPPORTING DOCUMENT POWER OF ATTORNEY Know all by these presents, that the undersigned hereby constitutes and appoints each of Leonard Schleifer, , Beverly Dubs, Stuart Kolinski, Murray Goldberg, and Douglas McCorkle signing singly, the undersigned's true and lawful attorney-in-fact to: (1) execute for and on behalf of the undersigned in the undersigned's capacity as a director of Regeneron Pharmaceuticals, Inc. (the "Company"), Forms 3, 4, and 5 in accordance with Section 16(a) of the Securities Exchange Act of 1934 and the rules thereunder; (2) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form 3, 4, or 5, complete and execute any amendment or amendments thereto, and timely file such form with the United States Securities and Exchange Commission and any stock exchange or similar authority; and (3) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-act on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion. The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934. This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4, and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact. IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 16th day of September, 2005. **/s/P. Roy Vagelos ------------------- Signature P, Roy Vagelos -------------- Print Name